Ani Pharmaceuticals Inc.
ANIP Nasdaq
SEC CIK 1023024
Follow Ani Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$290.8M
+27.6% vs same quarter last year
Net income
$35.1M
+32.1% vs same quarter last year
EPS, diluted
$1.51
+33.6% vs same quarter last year
Operating cash flow
$83.8M
+90.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $883.4M | $78M |
| FY24 | $614.4M | −$19M |
| FY23 | $486.8M | $19M |
| FY22 | $316.4M | −$48M |
| FY21 | $216.1M | −$43M |
| FY20 | $208.5M | −$22.5M |
| FY19 | $206.5M | $6.1M |
| FY18 | $201.6M | $15.5M |
| FY17 | $176.8M | −$1.1M |
| FY16 | $128.6M | $3.9M |
| FY15 | $76.3M | $15.4M |
| FY14 | $56M | $28.7M |
| FY13 | $30.1M | $301K |
| FY12 | $20.4M | −$1.5M |
| FY11 | $435.2K | −$51.6M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | 12.6% | 8.8% |
| FY24 | - | 0.1% | −3.1% |
| FY23 | - | 9.6% | 3.9% |
| FY22 | - | −11.2% | −15.2% |
| FY21 | - | −18.4% | −19.9% |
| FY20 | 58.2% | −7.7% | −10.8% |
| FY19 | 69.4% | 7.9% | 3% |
| FY18 | 63.8% | 17.5% | 7.7% |
| FY17 | 55.3% | 16% | −0.6% |
| FY16 | 62.1% | 15.6% | 3.1% |
| FY15 | 83.4% | 42.8% | 20.1% |
| FY14 | 79.5% | 35.7% | 51.4% |
| FY13 | 66.8% | 3% | 1% |
| FY12 | 55% | −0.2% | −7.4% |
| FY11 | - | - | −11859.7% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $171.4M |
| FY24 | $47.8M |
| FY23 | $110.1M |
| FY22 | −$40.1M |
| FY21 | $765K |
| FY20 | $9.1M |
| FY19 | $39M |
| FY18 | $61.3M |
| FY17 | $29.1M |
| FY16 | $22.9M |
| FY15 | $15.1M |
| FY14 | $20.9M |
| FY13 | −$5.7M |
| FY12 | −$429K |
| FY11 | −$48.6M |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | $1.2M | $12.2M |
| FY24 | $1.6M | $11M |
| FY23 | $1.6M | $5M |
| FY22 | $1.6M | $2M |
| FY21 | $190K | $890K |
| FY20 | $0 | $1.5M |
| FY19 | $0 | $1M |
| FY18 | - | $0 |
| FY17 | - | $0 |
| FY16 | - | $2.5M |
| FY15 | - | $0 |
| FY14 | - | $0 |
| FY13 | - | $433K |
| FY12 | - | $0 |
| FY11 | - | - |
- Ani Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Ani Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | 8.8% | −30.6% |
| FY24 | −3.1% | −47% |
| FY23 | 3.9% | −58% |
| FY22 | −15.2% | −80.4% |
| FY21 | −19.9% | −71.9% |
| FY20 | −10.8% | −62.2% |
| FY19 | 3% | −46.3% |
| FY18 | 7.7% | −49.6% |
| FY17 | −0.6% | −45.9% |
| FY16 | 3.1% | −36% |
| FY15 | 20.1% | −38.4% |
| FY14 | 51.4% | −35.5% |
| FY13 | 1% | −37.1% |
| FY12 | −7.4% | −29.1% |
| FY11 | −11859.7% | −27.9% |